image description

Press Releases

Press Releases

February 25, 2020
Revance to Participate in the Cowen 40th Annual Health Care Conference
NEWARK, Calif. --(BUSINESS WIRE)--Feb. 25, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the
February 12, 2020
Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027
NEWARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2020-- Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0 million aggregate principal
January 9, 2020
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P.
January 9, 2020
Revance Provides Corporate Update and Anticipated Milestones for 2020
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update and shared anticipated
Displaying 1 - 10 of 197